Clinical Trial

Study of GC101 TIL in Brain Glioma (Soochow2)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant glioma . Autologous TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-06-21; most recent amendment 2025-12-04.
Trial Details
NCT Number NCT04943913
Lead Sponsor Shanghai Juncell Therapeutics
Collaborators: Second Affiliated Hospital of Soochow University
Conditions Glioma
Enrollment 50 participants
Start Date 2021-05-06
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-05